



RealRate

PHARMACEUTICAL 2019

XYNOMIC PHARMACEUTICALS HOLDINGS INC. Rank 19 of 371







The relative strengths and weaknesses of XYNOMIC PHARMACEUTICALS HOLDINGS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XYNOMIC PHARMACEUTICALS HOLDINGS INC. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 107% points. The greatest weakness of XYNOMIC PHARMACEUTICALS HOLDINGS INC. is the variable Revenues, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 218%, being 549% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	150
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	767
Liabilities, Non-Current	0
Other Assets	63,311
Other Compr. Net Income	0
Other Expenses	836
Other Liabilities	0
Other Net Income	1,103
Property and Equipment	0
Research and Development	0
Revenues	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	63,461
Liabilities	767
Expenses	836
Stockholders Equity	62,694
Net Income	267
Comprehensive Net Income	267
Economic Capital Ratio	218%

